11 Jul 2019 14:16
Immunodiagnostic Systems Holdings PLC
Director/PDMR Dealing
11 July 2019
Immunodiagnostic Systems Holdings PLC ("IDS") a specialist producer of manual and automated diagnostic testing kits and instruments for the clinical and research markets, announces that it has granted the following options to persons discharging managerial responsibilities to acquire ordinary shares of 2p in the capital of the Company under the Company's Co-Investment Executive Option Scheme.
Position | Date of Grant | Number of Options | Exercise Price | |
Paul Martin | Finance Director | 28 March 2017 | 30,000 | £1.320 |
28 March 2017 | 9,000 | £2.775 | ||
29 March 2018 | 6,000 | £2.200 | ||
29 March 2018 | 6,300 | £2.900 | ||
28 March 2019 | 6,750 | £1.840 | ||
Jaap Stuut | CEO | 29 March 2018 | 7,500 | £2.200 |
28 March 2019 | 7,500 | £1.900 | ||
Nicola Mitton | HR Director | 29 March 2018 | 3,000 | £2.200 |
Under this scheme, participants who purchase ordinary shares in the Company ("Co-Investment Shares") are entitled to three share options for each Co-Investment Share they purchase. The exercise price for the options is set at the price the participant paid for each Co-Investment Share.
The options are subject to the satisfaction of performance conditions and vest after a period of 3 years. The Options are exercisable over the period of 10 years from the date of grant.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
For further information:
Immunodiagnostic Systems Holdings plc | Tel : +44 (0)191 519 0660 |
Paul Martin, Group Finance Director | |
Peel Hunt LLP | Tel : +44 (0)207 418 8900 |
James Steel | |
Oliver Jackson |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities / person closely associated | ||||||||||||||||||||||||||||||||
a. | Name | 1. Paul Martin 2. Jaap Stuut 3. Nicola Mitton | |||||||||||||||||||||||||||||||
2. | Reason for the notification | ||||||||||||||||||||||||||||||||
a. | Position/status | 1. Group Finance Director 2. Chief Executive Officer 3. HR Director | |||||||||||||||||||||||||||||||
a. | Initial notification /Amendment | Initial | |||||||||||||||||||||||||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||||||||||||||||||||||||
a. | Name | Immunodiagnostic Systems Holdings plc | |||||||||||||||||||||||||||||||
b. | LEI | 213800HZMYTD4NGF4L78 | |||||||||||||||||||||||||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||||||||||||||||||||||||
a. | Description of the Financial instrument, Type of instrument Identification code | Options over ordinary shares of 2p each in Immunodiagnostic Systems Holdings plc
Ordinary shares GB00B01YZ052 | |||||||||||||||||||||||||||||||
b. | Nature of the transaction | Grant of options | |||||||||||||||||||||||||||||||
c. | Price(s) and volume(s) |
| |||||||||||||||||||||||||||||||
d. | Aggregated information | N/A | |||||||||||||||||||||||||||||||
e. | Date of the transaction | see table above in section c | |||||||||||||||||||||||||||||||
f. | Place of the transaction | Outside trading venue - shares to be admitted to AIM market of London Stock Exchange plc on exercise of options | |||||||||||||||||||||||||||||||